INT65277

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1996
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 20
Total Number 20
Disease Relevance 4.61
Pain Relevance 11.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (Fst) nucleus (Fst) cytoplasm (Fst)
Anatomy Link Frequency
hippocampus 1
Fst (Mus musculus)
Pain Link Frequency Relevance Heat
Eae 48 100.00 Very High Very High Very High
analgesia 12 100.00 Very High Very High Very High
antinociception 9 100.00 Very High Very High Very High
antidepressant 76 99.98 Very High Very High Very High
cINOD 26 99.84 Very High Very High Very High
Inflammation 75 99.76 Very High Very High Very High
fluoxetine 19 99.50 Very High Very High Very High
tramadol 8 99.50 Very High Very High Very High
Hippocampus 63 99.40 Very High Very High Very High
opioid receptor 3 99.12 Very High Very High Very High
Disease Link Frequency Relevance Heat
Stress 25 100.00 Very High Very High Very High
INFLAMMATION 89 99.76 Very High Very High Very High
Depression 48 96.92 Very High Very High Very High
Pain 2 94.64 High High
Depressive Disorder 3 89.24 High High
Neurodegenerative Disease 132 88.80 High High
Gliosis 23 85.00 Quite High
Sprains And Strains 150 78.08 Quite High
Anxiety Disorder 18 72.16 Quite High
Cognitive Disorder 2 71.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Moreover, the reduction in the immobility time elicited by active doses of adenosine (10 mg/kg, i.p.) or fluoxetine (32 mg/kg, i.p.) in the FST was prevented by the pretreatment of mice with cromakalim (a K(+) channel opener, 10 microg/site, i.c.v.), without affecting the locomotion in an open-field.
Negative_regulation (prevented) of FST associated with adenocard and fluoxetine
1) Confidence 0.43 Published 2007 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 17296254 Disease Relevance 0 Pain Relevance 0.89
M. fragrans extract significantly decreased immobility periods of mice in both the FST and the TST.
Negative_regulation (decreased) of FST associated with eae
2) Confidence 0.41 Published 2006 Journal J Med Food Section Abstract Doc Link 16579733 Disease Relevance 0.09 Pain Relevance 0.47
Reduction in the immobility time elicited by an active dose of tramadol (40 mg/kg, p.o.) in the FST was prevented by pretreatment of mice with cromakalim (a K(+) channel opener, 10 microg/site, i.c.v.), without affecting the number of crossings and rearings in the OFT.
Negative_regulation (prevented) of FST associated with tramadol and eae
3) Confidence 0.40 Published 2009 Journal Eur. J. Pharmacol. Section Abstract Doc Link 19406118 Disease Relevance 0 Pain Relevance 0.87
The administration of folic acid by i.c.v. route also reduced the immobility time in the FST (10nmol/site) and in the TST (1-10nmol/site).
Negative_regulation (reduced) of FST
4) Confidence 0.38 Published 2008 Journal Neuropharmacology Section Abstract Doc Link 18078962 Disease Relevance 0.17 Pain Relevance 0.34
Folic acid administered by oral route (p.o.) produced a reduction in the immobility time in the FST (50-100mg/kg) and in the TST (10-50mg/kg).
Negative_regulation (reduction) of FST
5) Confidence 0.38 Published 2008 Journal Neuropharmacology Section Abstract Doc Link 18078962 Disease Relevance 0.18 Pain Relevance 0.30
ConBr (1-10 micro g/site, i.c.v.), but not ConA, produced a decrease in the immobility time in the FST (observed at the time points 15, 30, 60 and 120 min after the injection), without changing the locomotor activity in the open-field test.
Negative_regulation (decrease) of FST associated with eae
6) Confidence 0.37 Published 2006 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 16950503 Disease Relevance 0 Pain Relevance 0.22
The immobility time in the FST was significantly reduced by magnesium chloride administration (30-100 mg/kg, i.p.) without accompanying changes in ambulation when assessed in an open-field test.
Negative_regulation (reduced) of FST
7) Confidence 0.36 Published 2009 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 19059299 Disease Relevance 0 Pain Relevance 0.45
The combined treatment of sub-effective doses of zinc (hydroaspartate, 2.5 mg Zn/kg) and citalopram (15 mg/kg), fluoxetine (5 mg/kg) but not with reboxetine (2.5 mg/kg) significantly reduces the immobility time in the FST in mice.
Negative_regulation (reduces) of FST associated with eae and fluoxetine
8) Confidence 0.35 Published 2009 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 19150479 Disease Relevance 0.09 Pain Relevance 0.82
Moreover, while the antidepressant-like effect of zinc (5 mg/kg) in the FST was significantly blocked by pretreatment with inhibitor of serotonin synthesis, p-chlorophenylalanine (pCPA, 3x200 mg/kg), 5HT-2(A/C) receptor antagonist, ritanserin (4 mg/kg) or 5HT-1A receptor antagonist, WAY 1006335 (0.1 mg/kg), the zinc-induced reduction in the locomotor activity was not affected by these serotonin modulator agents.
Negative_regulation (blocked) of FST associated with antidepressant, antagonist, eae, 5ht and serotonin
9) Confidence 0.34 Published 2009 Journal Prog. Neuropsychopharmacol. Biol. Psychiatry Section Abstract Doc Link 19150479 Disease Relevance 0.08 Pain Relevance 0.94
In addition, the long-term treatment (28 days) with alpha-tocopherol (10mg/kg, p.o.) significantly reduced the immobility time in the FST.
Negative_regulation (reduced) of FST associated with eae
10) Confidence 0.33 Published 2010 Journal Behav. Brain Res. Section Abstract Doc Link 20144659 Disease Relevance 0.07 Pain Relevance 0.59
A single i.c.v. administration of alpha-tocopheryl phosphate, a water-soluble analogue of alpha-tocopherol, also reduced the immobility time in the FST (0.1 and 1 nmol/site) and in the TST (0.1 nmol/site).
Negative_regulation (reduced) of FST associated with eae
11) Confidence 0.32 Published 2010 Journal Behav. Brain Res. Section Abstract Doc Link 20144659 Disease Relevance 0.07 Pain Relevance 0.49
The acute oral treatment with alpha-tocopherol at the doses of 30 and 100mg/kg reduced the immobility time in the FST and in the TST.
Negative_regulation (reduced) of FST associated with eae
12) Confidence 0.32 Published 2010 Journal Behav. Brain Res. Section Abstract Doc Link 20144659 Disease Relevance 0.07 Pain Relevance 0.44
The immobility time in the FST was significantly reduced by CPMPH (0.1-10 mg/kg, i.p.), without accompanying changes in the ambulation in an open-field.
Negative_regulation (reduced) of FST
13) Confidence 0.31 Published 2005 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 16153700 Disease Relevance 0 Pain Relevance 0.53
The antidepressant-like effect of CPMPH (1 mg/kg, i.p.) in the FST was prevented by pre-treatment of mice with methysergide (2 mg/kg, i.p., a non-selective serotonin receptor antagonist), sulpiride (32 mg/kg, i.p., a D2 receptor antagonist) or yohimbine (1 mg/kg, i.p., an alpha2-adrenoceptor antagonist).
Negative_regulation (prevented) of FST associated with antidepressant, antagonist and serotonin
14) Confidence 0.30 Published 2005 Journal Pharmacol. Biochem. Behav. Section Abstract Doc Link 16153700 Disease Relevance 0 Pain Relevance 0.69
I.c.v. injection of GMP (320-480 nmol/site) also reduced the immobility in the FST without affecting ambulation.
Negative_regulation (reduced) of FST
15) Confidence 0.29 Published 2000 Journal Neuroreport Section Abstract Doc Link 10884029 Disease Relevance 0.09 Pain Relevance 0.17
First, clinically effective human treatments such as antidepressants reduce TST and FST immobility [9], [10]; second, manipulation of genes known to be involved in depression in humans affects TST and FST performance [11], [12], [13], [14]; and, finally, mice bred to express a behavioral or physiological “depressive” phenotype show increased immobility [15], [16], [17].
Negative_regulation (reduce) of FST associated with antidepressant and depression
16) Confidence 0.19 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012073 Disease Relevance 0.89 Pain Relevance 0.18
These results confirm that, in the KA-injured hippocampus, the inflammatory effects of FS-288 are reversed by NSAIDs.
Negative_regulation (reversed) of FS-288 in hippocampus associated with inflammation, cinod and hippocampus
17) Confidence 0.12 Published 2009 Journal Stem Cells (Dayton, Ohio) Section Body Doc Link PMC2733378 Disease Relevance 0.83 Pain Relevance 0.75
Second, antidepressant treatment reduces immobility in the TST and FST, while antipsychotic treatment has no effect (Crowley et al. 2004).
Negative_regulation (reduces) of FST associated with antidepressant
18) Confidence 0.11 Published 2010 Journal Mamm Genome Section Body Doc Link PMC2890984 Disease Relevance 0.80 Pain Relevance 0.30
Thus, we provided evidence that central KATP channels participate in the production of FS-SIA but not production of SW- or PSY-SIA; and we suggest that glibenclamide, through closing of KATP channels, suppresses mu-opioid receptor functions, which subsequently leads to the inhibition of FS-SIA since antinociception is produced by the activation of mu-receptors.
Negative_regulation (inhibition) of FS-SIA associated with antinociception, opioid receptor and analgesia
19) Confidence 0.07 Published 1996 Journal Jpn. J. Pharmacol. Section Abstract Doc Link 8854212 Disease Relevance 0.22 Pain Relevance 1.08
On the other hand, oral gluten exorphin A5 suppressed the endogenous pain-inhibitory system, i.e., antinociception induced by socio-psychological- (PSY-) stress (SIA) using a communication box; intraperitoneal gluten exorphin A5 abolished both footshock- (FS-) stress-induced antinociception (SIA) and PSY-SIA; and i.c.v. gluten exorphin A5 suppressed FS-SIA, but rather potentiated PSY-SIA.
Negative_regulation (suppressed) of FS-SIA associated with stress, antinociception and pain
20) Confidence 0.05 Published 2000 Journal Jpn. J. Pharmacol. Section Abstract Doc Link 11138726 Disease Relevance 0.95 Pain Relevance 1.30

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox